辉瑞获黑石生命科学最高15亿美元资助：共同推进每月一次GLP-1减肥药berobenatide，资助期至2028年
纽约与马萨诸塞州 Cambridge 消息，辉瑞公司（Pfizer）与黑石生命科学（Blackstone Life Sciences）11月11日宣布达成战略共同资助协议：黑石管理的基金将为辉瑞在研药物 berobenatide 承担最高15亿美元的开发成本，资助期至2028年。
berobenatide（代号 PF’3944）是一款在研的潜在同类首创每月一次给药的 GLP-1 受体激动剂肽类药物，用于慢性体重管理及肥胖相关疾病，包括膝骨关节炎与阻塞性睡眠呼吸暂停。作为交换，黑石将有资格获得里程碑付款，前提是注射用 berobenatide 每月给药单药疗法用于慢性体重管理获得美国监管批准，并达成若干商业销售里程碑。
两家公司强调，黑石不取得 berobenatide 的任何权利或所有权，辉瑞保留该项目的全部运营控制与决策权；黑石的永久私募股权策略 BXPE 旗下基金将与黑石生命科学旗下基金共同参与此次投资。
辉瑞表示，计划在2026年推进20多项肥胖及相关合并症试验，其中包括 berobenatide 已在进行和计划中的10项3期试验。
（来源：辉瑞）
Pfizer Secures Up to $1.5 Billion From Blackstone Life Sciences to Fund Monthly GLP-1 Obesity Drug Berobenatide Through 2028
NEW YORK and CAMBRIDGE, Massachusetts — Pfizer Inc. and Blackstone Life Sciences announced a strategic co-funding agreement on November 11 under which funds managed by Blackstone will pay up to $1.5 billion of development costs through 2028 for berobenatide, Pfizer's investigational monthly GLP-1 receptor agonist.
Berobenatide (PF'3944) is a potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions, including knee osteoarthritis and obstructive sleep apnea. In exchange for the funding, Blackstone will be eligible to receive milestone-based payments, subject to U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management and the achievement of certain commercial sales milestones.
The companies stressed that Blackstone does not acquire any rights or ownership in berobenatide, and that Pfizer retains full operational control and decision-making over the program. Funds managed by Blackstone's perpetual private equity strategy BXPE will invest alongside Blackstone Life Sciences funds in the transaction.
Pfizer said it plans to advance more than 20 trials for obesity and related comorbidities in 2026, including 10 ongoing and planned Phase 3 trials for berobenatide.
(Source: Pfizer)
来源：辉瑞
发布：GSM·美国（发布链接）
图片来源：图：位于纽约的辉瑞全球总部入口。照片：Coolcaesar 摄，CC BY-SA 4.0，经 Wikimedia Commons。 / Photo: Entrance to Pfizer's world headquarters in New York. Photo by Coolcaesar, CC BY-SA 4.0, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
